265 related articles for article (PubMed ID: 17580188)
1. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience.
Sucak GT; Aki ZS; Yagcí M; Yegin ZA; Ozkurt ZN; Haznedar R
Transplant Proc; 2007 Jun; 39(5):1558-63. PubMed ID: 17580188
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation.
Yakushijin K; Matsui T; Okamura A; Yamamoto K; Ito M; Chihara K
Kobe J Med Sci; 2005; 51(3-4):55-65. PubMed ID: 16444097
[TBL] [Abstract][Full Text] [Related]
3. [Defibrotide therapy for patients with sinusoidal obstruction syndrome after hematopoietic stem cell transplantation].
Yakushijin K; Okamura A; Ono K; Kawano Y; Kawano H; Funakoshi Y; Kawamori Y; Nishikawa S; Minagawa K; Sada A; Shimoyama M; Yamamoto K; Katayama Y; Matsui T
Rinsho Ketsueki; 2009 Jan; 50(1):3-8. PubMed ID: 19225222
[TBL] [Abstract][Full Text] [Related]
4. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
Ho VT; Revta C; Richardson PG
Bone Marrow Transplant; 2008 Feb; 41(3):229-37. PubMed ID: 17994121
[TBL] [Abstract][Full Text] [Related]
5. Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation.
Park M; Park HJ; Eom HS; Kwon YJ; Park JA; Lim YJ; Yoon JH; Kong SY; Ghim TT; Lee HW; Yun T; Park BK
Ann Transplant; 2013 Jan; 18():36-42. PubMed ID: 23792499
[TBL] [Abstract][Full Text] [Related]
6. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
[TBL] [Abstract][Full Text] [Related]
7. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
8. Defibrotide treatment but not prophylaxis is useful in hepatic sinusoidal obstruction syndrome in children undergoing autologous stem cell transplant following high-dose chemotherapy: A single-center experience from the Royal Marsden Hospital, UK.
Roy Moulik N; Johnson I; Van Bruggen L; Petterson T; Mycroft J; Vaidya SJ
Pediatr Blood Cancer; 2020 Nov; 67(11):e28677. PubMed ID: 32865880
[TBL] [Abstract][Full Text] [Related]
9. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
10. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
11. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
[TBL] [Abstract][Full Text] [Related]
12. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
13. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
[TBL] [Abstract][Full Text] [Related]
14. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
Ho VT; Linden E; Revta C; Richardson PG
Semin Thromb Hemost; 2007 Jun; 33(4):373-88. PubMed ID: 17525895
[TBL] [Abstract][Full Text] [Related]
15. Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.
Shah MS; Jeevangi NK; Joshi A; Khattry N
J Cancer Res Ther; 2009; 5(4):312-4. PubMed ID: 20160371
[TBL] [Abstract][Full Text] [Related]
16. Drug safety evaluation of defibrotide.
Richardson PG; Corbacioglu S; Ho VT; Kernan NA; Lehmann L; Maguire C; Maglio M; Hoyle M; Sardella M; Giralt S; Holler E; Carreras E; Niederwieser D; Soiffer R
Expert Opin Drug Saf; 2013 Jan; 12(1):123-36. PubMed ID: 23228043
[TBL] [Abstract][Full Text] [Related]
17. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
[TBL] [Abstract][Full Text] [Related]
18. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
19. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention.
Corbacioglu S; Greil J; Peters C; Wulffraat N; Laws HJ; Dilloo D; Straham B; Gross-Wieltsch U; Sykora KW; Ridolfi-Lüthy A; Basu O; Gruhn B; Güngör T; Mihatsch W; Schulz AS
Bone Marrow Transplant; 2004 Jan; 33(2):189-95. PubMed ID: 14661036
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of defibrotide in the prevention of hepatic venooclusive disease among adult patients receiving allogeneic hematopoietic cell transplantation: A retrospective single center experience.
Kayikci O; Akpinar S; Tekgunduz E
Transfus Apher Sci; 2022 Feb; 61(1):103369. PubMed ID: 35120824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]